Ketoconazole

證據等級: L5

預測適應症: 1 個

Ketoconazole: From Fungal Infections to Acne

One-Sentence Summary

Ketoconazole is a broad-spectrum imidazole antifungal agent, classically used to treat fungal infections (including cutaneous candidiasis, tinea, and pityriasis versicolor) and, at systemic doses, to suppress cortisol production in Cushing’s syndrome. The TxGNN model predicts it may be effective for Acne (disease), with 1 active clinical trial and 15 publications currently supporting this direction. Evidence is grounded in two mechanistic pathways: anti-Malassezia activity (addressing fungal folliculitis often misdiagnosed as acne) and anti-androgenic effects via steroidogenesis inhibition.

Quick Overview

Item	Content
Original Indication	Antifungal (fungal skin infections, candidiasis, pityriasis versicolor; systemic: Cushing’s syndrome cortisol suppression)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.80%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails (Topical Route Only)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, ketoconazole is an imidazole antifungal that inhibits cytochrome P450–dependent 14α-lanosterol demethylase, blocking ergosterol biosynthesis in fungal cell membranes. At higher concentrations, it also inhibits mammalian steroidogenic enzymes including CYP17A1 and CYP11A1, reducing adrenal and gonadal androgen production — a property that underpins its use in Cushing’s syndrome and PCOS-related hyperandrogenism.

Two mechanistic pathways connect ketoconazole to acne. First, the anti-fungal pathway: Malassezia (formerly Pityrosporum ovale/orbiculare), a lipophilic yeast resident in pilosebaceous units, drives Pityrosporum folliculitis — a condition clinically indistinguishable from comedonal acne vulgaris. Topical ketoconazole directly suppresses this organism. Second, the anti-androgenic pathway: androgens stimulate sebaceous gland activity, and ketoconazole’s CYP inhibition reduces circulating androgens, offering theoretical benefit in hormonal acne (e.g., PCOS-associated acne). In vitro work has additionally demonstrated direct inhibition of Propionibacterium acnes lipase activity, attenuating the inflammatory metabolite cascade central to conventional acne pathogenesis.

The predicted new indication is therefore not speculative — topical ketoconazole 2% cream is already under active clinical investigation as an alternative to adapalene in mild acne (NCT07237763). While systemic use raises significant safety concerns (658 drug interactions, hepatotoxicity), the topical formulation has minimal systemic absorption, substantially widening the safety margin for this specific application.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07237763	NA	Active, Not Recruiting	52	Head-to-head RCT comparing topical ketoconazole 2% cream vs. topical adapalene 2% cream over 12 weeks in mild comedonal and papulopustular acne; evaluating whether ketoconazole offers a viable alternative with fewer side effects and better tolerability

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28111792	2017	In vitro study	Microbiology and Immunology	Ketoconazole inhibits P. acnes lipase activity, reducing generation of pro-inflammatory fatty acids from sebum; also inhibits P. acnes growth — supports direct antibacterial/anti-inflammatory mechanism in acne
20045949	2010	In vitro study	Biological & Pharmaceutical Bulletin	Azole antifungals including ketoconazole demonstrate activity against P. acnes in vitro; relevant given rising antibiotic-resistant P. acnes strains
8593718	1995	Case Series	Clinical and Experimental Dermatology	62 patients with Pityrosporum folliculitis (frequently misdiagnosed as acne vulgaris) in Saudi Arabia; confirms ketoconazole as effective treatment for this acne-mimicking condition
8255067	1993	Review	The Keio Journal of Medicine	Comprehensive review of Pityrosporum ovale as opportunistic pathogen in pityriasis versicolor, folliculitis, and seborrhoeic dermatitis; mechanistic basis for antifungal use in acne-spectrum disease
33216275	2021	Phase 3 Open-Label Study	Pituitary	Levoketoconazole (ketoconazole enantiomer) in Cushing’s syndrome (SONICS trial): clinical improvement in acne and other hyperandrogenic skin signs, supporting the anti-androgenic pathway
8090657	1993	Clinical Study	Polski Tygodnik Lekarski	Ketoconazole included in treatment of hyperandrogenic manifestations in PCOS, with reduction of acne and seborrhoea within 3 months; early clinical evidence of anti-androgenic efficacy
12566804	2003	Review	Dermatology (Basel)	Comprehensive review of systemic acne treatment options; contextualises where anti-androgens and anti-fungals fit in the therapeutic ladder
19445767	2009	Review	BMJ Clinical Evidence	PCOS review: acne is a key presenting feature of hyperandrogenic PCOS; supports rationale for androgen-targeting therapy including ketoconazole
8629828	1996	Case Series	Archives of Dermatology	Neonatal Malassezia furfur pustulosis frequently misidentified as neonatal acne; underscores the diagnostic overlap between fungal folliculitis and acne, where ketoconazole would be appropriate
32872149	2020	Review	Pharmaceuticals (Basel)	Adapalene therapeutic review — the comparator drug in the active RCT (NCT07237763); provides mechanistic context for the head-to-head comparison with topical ketoconazole

India Market Information

Ketoconazole currently has no registered products in the Indian market based on the available regulatory data.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No registrations on record

Note: Ketoconazole oral formulations have faced regulatory restrictions globally (including FDA and EMA black-box warnings for hepatotoxicity). Topical formulations generally remain available and are distinct from the systemic safety concerns. Market entry for the acne indication would likely follow a topical-only pathway.

Safety Considerations

Drug Interactions (Total: 658 interactions identified)

Ketoconazole carries an exceptionally high drug interaction burden, primarily due to potent CYP3A4 inhibition. Key interactions include:

Severity	Representative Interactions
Major	Loperamide, Triamcinolone, Budesonide (risk of systemic corticosteroid toxicity / QT prolongation)
Moderate	Famotidine, Ranitidine, Rabeprazole, Omeprazole (reduced ketoconazole absorption due to gastric pH elevation); Hydrocortisone, Dexamethasone, Betamethasone (CYP3A4-mediated corticosteroid accumulation); Pioglitazone, Aprepitant, Atropine, Hyoscyamine, Bisacodyl, Methscopolamine, Alosetron
Minor	Amphotericin B, Amphotericin B lipid complex

For topical use specifically: systemic absorption of ketoconazole 2% cream is negligible under normal conditions, substantially reducing the clinical relevance of the above interactions. The interaction profile above reflects systemic (oral) administration and should not be applied directly to topical formulations.

Key Safety Note: Detailed prescribing warnings and contraindications for oral ketoconazole (hepatotoxicity, QT prolongation, adrenal insufficiency risk) should be verified directly from the package insert. These are well-documented in global regulatory agency labelling.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic case for topical ketoconazole in acne is biologically coherent via two independent pathways (anti-Malassezia/anti-P. acnes and anti-androgenic), and is corroborated by an active randomised controlled trial (NCT07237763) directly comparing it to a first-line acne therapy. The L3 evidence level reflects converging observational, in vitro, and clinical evidence — sufficient to justify a structured development programme for the topical route. Systemic use is not recommended given the 658-interaction burden and global hepatotoxicity warnings.

To proceed, the following is needed:

Retrieve topical-specific safety data: Obtain the package insert for ketoconazole 2% topical cream to document local tolerability (contact sensitisation, irritation), as distinct from systemic hepatotoxicity concerns
Await NCT07237763 results: The active RCT comparing ketoconazole 2% vs adapalene 2% in mild acne will directly answer the efficacy question; estimated completion December 2025
Confirm MOA data (DrugBank): Formally document the CYP17A1/CYP11A1 inhibition and anti-Malassezia mechanism to complete the mechanistic dossier
Regulatory pathway assessment: Determine whether a new drug application for the acne indication requires a full NDA or can be filed as a line extension/supplemental application for the topical formulation in India
Subgroup analysis plan: Define whether the target population is fungal folliculitis (anti-Malassezia pathway), hormonal/PCOS acne (anti-androgenic pathway), or conventional acne vulgaris (anti-P. acnes pathway) — these require different trial designs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.